BioCentury
ARTICLE | Company News

Teva, Impax, Allergan deal

July 25, 2016 7:00 AM UTC

Teva will sell a portfolio of generic products to Impax for $586 million. The deal includes 15 marketed generics, three approved products that have not yet launched, two products that are pending FDA ...